Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab(TM) Platform

Avricore Health Scales UK NHS Pilot But Profitability Timeline Remains Distant

By The Northwire Desk — AI Analysis Apr 21, 2026 · 06:30 AVCR · 0.065 Avricore Health Inc.
Executive Summary
  • The most recent release (April 21, 2026) confirms operational milestones for the HealthTab™ platform in London community pharmacies.
  • Over 3,500 patients screened across North East and North Central London with a monthly per-location average 10 times higher than previous Canadian operations.
  • Strategic roadmap targets expansion to over 500 active UK locations by mid-2027, with an immediate target of more than 100 pharmacy sites in Q2 2026.
  • Financial projections indicate a return to profitability by Q3 2027 following a transition into the UK NHS market.
  • Revenue model shifts from testing fees to monthly subscription revenue expected in the second half of 2026.
  • Historical context shows progression from a November 2025 pilot launch (Barts Health NHS Trust) to January 2026 expansion announcements, culminating in this April milestone update.
Material Impact
  • The news validates previous strategic plans rather than introducing unexpected breakthroughs or major capital raises.
  • Operational metrics (3,500 patients screened) demonstrate scalability but do not yet translate to realized revenue as subscription models begin later in 2026.
  • Profitability target of Q3 2027 is a significant timeline extension from current operations, indicating continued cash burn risk before earnings generation.
  • The announcement aligns with the January expansion roadmap and November pilot integration, suggesting execution is on track but incremental.
  • No material negative surprises regarding regulatory hurdles or partnership cancellations were noted in this release.
AVCR · Price
Company Overview
  • Avricore Health operates a point-of-care testing platform (HealthTab™) designed for community pharmacies.
  • Flagship project integrates analyzers with cloud software to enable real-time analytics and public-health reporting within NHS pathways.
  • Primary focus is shifting care from hospitals to community settings, specifically targeting cardiovascular risk screening and chronic condition management.
  • Platform includes instruments, workflows, training, and support, positioning itself as a turnkey solution for pharmacy-based testing.
Read the original news release →

More from Avricore Health Inc.

Jun 17, 2026 · 06:30

Avricore Health Closes $1.254 Million Financing

Financings May 20, 2026 · 06:55

Avricore Health Raises $1.25M Amidst UK Expansion Push; Dilution Concerns Loom

Financings Jan 14, 2026 · 09:46

HealthTab(TM) to Expand Across North East London

Production / Operations Nov 27, 2025 · 19:09

Avricore's HealthTab supports inclisiran delivery

M&A / Property Nov 27, 2025 · 17:00

HealthTab(TM) to Power NHS Pilot

Production / Operations